September 2023 Snap Recap: Prostate Cancer Awareness, Breast Cancer QOL Insights

News
Video

In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.

As we enter the final leg of 2023, CancerNetwork® looks back on the biggest news pieces of September as decided on by our readers. Popular selections included articles on the clearance of an investigational new drug application for a CDK12/13 inhibitor, the quality-of-life benefits of a certain diet and exercise intervention in breast cancer, how AI may help with diagnosis and risk stratification in prostate cancer, the impact of adaptive stereotactic body radiotherapy on toxicities in prostate cancer, and recurrence risk following breast-conserving surgery and endocrine therapy for luminal breast cancer.1-4

Full versions of the article are referenced below in the order that they appear in the show:

References

  1. Carrick Therapeutics announces U.S. FDA clearance of IND for CT7439, a first-in-class inhibitor of CDK12/13. News release. Carrick Therapeutics. September 7, 2023. Accessed September 7, 2023. https://bit.ly/3Z9GoN9
  2. Leeman JE, Shin KY, Chen YH, et al. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer. Published online July 24, 2023. doi:10.1002/cncr.34836
  3. Sanft T, Harrigan M, McGowan C, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. Published online September 1, 2023. doi:10.1200/JCO.23.00871
  4. Whelan TJ, Smith S, Parpia S, et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389:612-619. doi:10.1056/NEJMoa2302344
Recent Videos
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Related Content
Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Pembrolizumab/Cisplatin Combo Shows Promise in Small Cell Bladder Cancer, Neuroendocrine Prostate Cancer

Tim Cortese
November 18th 2024
Article

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Denileukin Diftitox Combo Shows Promising ORR and CBR in Solid Tumors

Tim Cortese
November 14th 2024
Article

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

SBRT Emerges as Viable Treatment for Localized Prostate Cancer

Tim Cortese
November 12th 2024
Article

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Camizestrant Significantly Improves PFS in HER2– Breast Cancer

Tim Cortese
November 12th 2024
Article

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.